| Name | Title | Contact Details |
|---|
Cecelia Health partners with health plans/providers seeking to improve quality measures, and pharmaceutical/medical device companies seeking to improve adherence.
Fort Hudson Nursing Home Inc is a Fort Edward, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Established over 25 years ago, Medcan is a global leader in assessing clients` overall well-being and inspiring them to live well. We partner with over 1,000 corporate accounts and 40,000 clients to set and achieve health and wellness goals.
US Post Acute Care is a Management Services Organization providing value-added service to clinical practice groups specializing in the care of patients in the post-acute setting. An organization with a national footprint, US Post Acute Care provides a full array of management services including billing, recruiting, training, compliance, analytics, and practice development. US Post Acute Care structures its services offering both to serve the needs as well as leverage the capabilities of its clinicians: the physicians and advanced practitioners dedicated to improving the quality of care for their patients. US Post Acute Care has designed and launched a proprietary clinical excellence program called SmartPAC™, a comprehensive clinical program for post-acute care designed to enable practitioners to improve patient outcomes with better quality care. Please
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.